BEIJING, December 8, SinoCast -- US pharmaceutical giant Bristol-Myers Squibb on December 6 announced the end of initiative promotion of OTC products in China.
The company needs to lay off about 150 people, will send salaries to the laid-off staff to the end of February 2017 and announced its "N +1 +2 * average monthly income" compensation program.
The company peeled off its HIV drug research and development line this February, gave up the diabetes market this March, abolished the tumor division's Taxol product group and abandoned the entire cardiovascular business at the end of this August.
After the move, the company will just have virus and tumor business units in China.
© Sinocast, source Sinocast Beats